Rosacea Treatment Market Is Estimated To Witness High Growth Owing To Increased Awareness Regarding Rosacea
The Rosacea Treatment Market is estimated to be valued at US$ 1.91 Bn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Rosacea is a long-term skin condition that mainly affects the face. It causes redness, visible blood vessels, swelling and acne-like bumps. The four main subtypes of rosacea are erythematotelangiectatic, papulopustular, phymatous and ocular. Topical and oral antibiotics, chemical peels, laser procedures, photodynamic therapy and intense pulsed light therapy are some of the treatments used for rosacea management and prevention of progression of symptoms.
Market key trends:
Increased awareness regarding rosacea through various awareness programs run by non-profit organizations as well as private players is a major factor driving the market growth. For instance, National Rosacea Society (NRS) conducts various educational seminars and campaigns to educate people about rosacea. Moreover, the availability of various treatment options and emergence of combination therapies with improved efficacy are contributing to the market growth. Growing demand for minimally invasive procedures for rosacea treatment such as laser treatments, photodynamic therapy and intense pulsed light therapy is another key trend in the market.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate in the Rosacea Treatment Market as it requires heavy R&D investment and clinical trials. Starting a new pharmaceutical company will require huge capital investment.
Bargaining power of buyers: The bargaining power of buyers is high as the market has many global players providing alternative treatment options. Buyers can negotiate on price and quality of products.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as raw material suppliers are fragmented. However, suppliers of advanced active pharmaceutical ingredients have some control over pricing.
Threat of new substitutes: The threat of new substitutes is low due to lack of substitutes for rosacea treatment. However, alternative treatment methods can be adopted.
Competitive rivalry: Intense competition exists between major players to increase their market share.
SWOT Analysis
Strength: Wide range of product offerings and strong R&D capabilities of key players. Increasing awareness about rosacea treatment options.
Weakness: High costs associated with new drug development and clinical trials. Side effects of few medications.
Opportunity: Growing geriatric population prone to rosacea. Untapped markets in developing regions offer high growth potential.
Threats: Price erosion due to patent expiries. Stringent regulations for drug approvals.
Key Takeaways
The Global Rosacea Treatment Market Trend is expected to witness high growth, exhibiting CAGR of 6.3% over the forecast period, due to increasing awareness about treatment and management of rosacea symptoms. North America dominated the market in 2022 owing to advanced healthcare infrastructure and growing per capita healthcare spending in the US and Canada.
Regionally, Asia Pacific is expected to exhibit the fastest growth during the forecast period. Countries such as China, India, Japan and South Korea offer lucrative growth opportunities with rising medical tourism, healthcare expenditures and growing middle class income group.
Key players operating in the Rosacea Treatment market are Galderma SA, Allergan plc (AbbVie Inc.), Bayer AG, Pfizer Inc., Leo Pharma A/S, Sol-Gel Technologies Ltd., Foamix Pharmaceuticals Ltd., Mayne Pharma, Group Limited, AnaptysBio, Inc., Mylan N.V. The major players are focusing on enhancing their product portfolios through strategic collaborations and new product launches.